EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025) | |
Format: Date: Time: | Corporate presentation Monday, March 3, 2025 11:10AM ET |
Location: Link: | Boston, MA /webcast/cowen177/register.aspx?conf=cowen177&page=xoma&url=https://wsw.com/webcast/cowen177/xoma/2033463 |
Leerink 2025 Global Healthcare Conference (March 9-12, 2025) | |
Format: | Fireside chat |
Date: | Monday, March 10, 2025 |
Time: | 2:20PM ET |
Location: Link: | Miami Beach, FL /webcast/leerink38/register.aspx?conf=leerink38&page=xoma&url=https://wsw.com/webcast/leerink38/xoma/2233817 |
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
XOMA Investor Contact | XOMA Media Contact |
Juliane Snowden | Kathy Vincent |
XOMA Royalty | KV Consulting & Management |
+1 646-438-9754 | +1 310-403-8951 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$24.32 |
Daily Change: | 0.88 3.75 |
Daily Volume: | 13,701 |
Market Cap: | US$286.490M |
March 17, 2025 February 04, 2025 December 02, 2024 November 07, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load